Tufts CSDD Reports Increased Collaboration to Reduce Development Risk
August 7, 2014
Applied Clinical Trials
According to Tufts CSDD R&D Management Report, more than half of all new drugs approved in the United States between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities.
According to Tufts CSDD R&D Management Report, more than half of all new drugs approved in the United States between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities. The report is based on insights gathered at an executive roundtable of biopharma R&D leaders. Other points included that risk-sharing partnerships are most likely to succeed when governed by a charter that ensures executive engagement, clearly delineates roles and tasks for each organization and key individuals, and defines success metrics and quality measures
